Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/34575
Title: Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study
Authors: Charleer, Sara
De Block, Christophe
Van Huffel, Liesbeth
Broos, Ben
FIEUWS, Steffen 
Nobels, Frank
Mathieu, Chantal
Gillard, Pieter
Issue Date: 2020
Publisher: 
Source: Diabetes care, 43 (2) , p. 389 -397
Abstract: OBJECTIVE In 2016, nationwide reimbursement of intermittently scanned continuous glucose monitoring (isCGM) for people living with type 1 diabetes treated in specialist diabetes centers was introduced in Belgium. We undertook a 12-month prospective observational multicenter real-world study to investigate impact of isCGM on quality of life and glycemic control. RESEARCH DESIGN AND METHODS Between July 2016 and July 2018, 1,913 adults with type 1 diabetes were consecutively recruited in three specialist diabetes centers. Demographic, metabolic, and quality of life data were collected at baseline, 6 months, and 12 months of standardized clinical follow-up. The primary end point was evolution of quality of life from baseline to 12 months. Secondary outcome measures were, among others, change in HbA(1c), time spent in different glycemic ranges, occurrence of acute diabetes complications, and work absenteeism. RESULTS General and diabetes-specific quality of life was high at baseline and remained stable, whereas treatment satisfaction improved (P < 0.0001). Admissions for severe hypoglycemia and/or ketoacidosis were rare in the year before study (n = 63 out of 1,913; 3.3%), but decreased further to 2.2% (n = 37 out of 1,711; P = 0.031). During the study, fewer people reported severe hypoglycemic events (n = 280 out of 1,913 [14.6%] vs. n = 134 out of 1,711 [7.8%]; P < 0.0001) or hypoglycemic comas (n = 52 out of 1,913 [2.7%] vs. n = 18 out of 1,711 [1.1%]; P = 0.001) while maintaining HbA(1c) levels. Fewer people were absent from work (n = 111 out of 1,913 [5.8%] vs. n = 49 out of 1,711 [2.9%]; P < 0.0001). Time spent in hypoglycemia significantly decreased in parallel with less time in range and more time in hyperglycemia. Eleven percent (n = 210) of participants experienced skin reactions, leading to stopping of isCGM in 22 participants (1%). CONCLUSIONS Nationwide unrestricted reimbursement of isCGM in people with type 1 diabetes treated in specialist diabetes centers results in higher treatment satisfaction, less severe hypoglycemia, and less work absenteeism, while maintaining quality of life and HbA(1c).
Document URI: http://hdl.handle.net/1942/34575
ISSN: 0149-5992
e-ISSN: 1935-5548
DOI: 10.2337/dc19-1610
ISI #: WOS:000508199900028
Category: A1
Type: Journal Contribution
Validations: ecoom 2021
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
389.full.pdfPublished version1.11 MBAdobe PDFView/Open
Show full item record

WEB OF SCIENCETM
Citations

149
checked on Mar 22, 2024

Page view(s)

18
checked on Jun 9, 2022

Download(s)

2
checked on Jun 9, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.